A ‘designer’ manganese-peptide antioxidant of the world’s toughest bacterium, combined with radiation, have shown to be successful in the development of a vaccine to counter Venezuelan Equine Encephalitis Virus (VEEV), a biothreat agent, and Chikungunya virus, a mosquito-borne illness causing severe outbreaks around the world, according to a study “Deinococcus Mn2+-Peptide Complex: A Novel Approach to Alphavirus Vaccine Development,” published online May 30 in the journal, Vaccine, published by Elsevier, http://www.sciencedirect.com/
Effective vaccines depend upon the human immune system recognizing a biological structure that is similar to that of a disease-causing organism. A manganese-peptide antioxidant complex of Deinococcus, developed by Uniformed Services University of the Health Sciences (USU) pathology professor Dr. Michael J. Daly and his team, has the remarkable property of protecting proteins from ionizing radiation damage but not protecting the genetic material (DNA or RNA) in viruses and bacteria. Using D. radiodurans, listed in the Guinness Book of World Records as “the world’s toughest bacterium” and which can withstand 3,000 times the levels of gamma radiation that human cells can, Daly found that a disease-causing organism (pathogen) can be exposed to gamma radiation in the presence of a Deinococcus Mn complex, and rendered non-replicative (killed) by overwhelming genetic damage, but still maintain the shape of key surface proteins needed to mount a highly protective immune response. This approach was successfully implemented on viruses for the first time by scientists in the USU lab of the late Dr. Radha K. Maheshwari to produce vaccines against VEEV and Chikungunya virus.
This approach offers a simple, rapid, cost effective and potentially universal inactivation strategy that can be applied to any pathogen requiring immediate attention, for example, Ebola and Zika viruses.
“Application of this methodology has the potential to revolutionize all future vaccine development” says Dr. Paridhi Gupta, a scientist in the Maheshwari laboratory, and the study’s co-lead author.
The Latest on: Vaccine development
- Global BCG Vaccine Market 2020 Analysis by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast by 2025on February 27, 2020 at 10:46 pm
A collective analysis on 'BCG Vaccine market' by 360 Market Updates, offers an exhaustive study based on current trends influencing this vertical throughout assorted geographies. Key information ...
- Israeli scientists: 'In a few weeks, we will have coronavirus vaccine'on February 27, 2020 at 4:42 pm
“Given the urgent global need for a human coronavirus vaccine, we are doing everything we can to accelerate development,” MIGAL CEO David Zigdon said. The vaccine could “achieve safety approval in 90 ...
- Coronavirus vaccine development could cost $1Bon February 27, 2020 at 7:35 am
Continue Reading Below "When we talk about vaccine development programs, a typical vaccine development program from discovery to licensure can cost up to a billion dollars and take up to a decade," ...
- COVID-19 vaccine developmenton February 27, 2020 at 5:24 am
Scientists have recently identified a set of potential vaccine targets for SARS-CoV-2 coronavirus, to guide experimental efforts towards vaccine development against novel pneumonia (COVID-19). A team ...
- Novavax Advances Development of Novel COVID-19 Vaccineon February 26, 2020 at 12:32 pm
Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its efforts to develop a novel vaccine to ...
via Google News and Bing News